Home Biosimilar Antibodies GPCR & G Protein CXCR inhibitor Anti-CXCR3 / GPR9 / CD183
For research use only. Not for use in humans.

Anti-CXCR3 / GPR9 / CD183

Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

Anti-CXCR3 / GPR9 / CD183

Quality Control

Batch: A270601 Purity: 99% Protein concentration: 9.04mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CXCR1 CXCR2 CXCR4 CXCR3 Others
WZ811 20
Mavorixafor 0
AMG 487 4
Motixafortide (BKT140) 1 cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123) 8
MSX-122 1
LY2510924 2
Reparixin (Repertaxin) 24 CXCL8
SB 225002 91
Ladarixin 0
SB 265610 2
Balixafortide (POL6326) 0
SX-682 3
TAK-779 0 CCR5
MSX-130 0
MSX-127 0
AZD5069 3
Danirixin (GSK1325756) 2 CXCL8
LIT-927 5 CXCL12
AMD3465 hexahydrobromide 1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.
References

Product Details

Molecular Weight 146.38
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.